All In Biotech

Drug Trial Radar · NCT02757768

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 715 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

715

Actual

Start

Jun 13, 2016

Primary completion

Aug 14, 2018

Study completion Sep 11, 2018

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
May 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH).

Conditions

  • Benign Prostatic Hyperplasia
  • Overactive Bladder

Interventions

  • MirabegronDrug

    Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.

  • PlaceboDrug

    Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.

  • Tamsulosin HydrochlorideDrug

    Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per DayTime frame: Baseline and Week 12

Locations

79 sites in 9 countries. Site status is shown where the registry gives one.

  • Site US01009

    Homewood, Alabama

  • Site US01005

    Huntsville, Alabama

  • Site US01012

    Anchorage, Alaska

  • Site US01070

    Hawaiian Gardens, California

  • Site US01081

    Los Angeles, California

  • Site US01021

    Murrieta, California

  • Site US01068

    San Diego, California

  • Site US01064

    Valley Village, California

  • Site US01097

    Englewood, Colorado

  • Site US01026

    Pompano Beach, Florida

  • Site US01025

    St. Petersburg, Florida

  • Site US01027

    Wellington, Florida

  • Site US01034

    West Des Moines, Iowa

  • Site US01094

    Shreveport, Louisiana

  • Site US01041

    Baltimore, Maryland

  • Site US01016

    Boston, Massachusetts

  • Site US01003

    Watertown, Massachusetts

  • Site US01060

    Kansas City, Missouri

  • Site US01067

    Billings, Montana

  • Site US01061

    Omaha, Nebraska

  • Site US01029

    Edison, New Jersey

  • Site US01031

    Albuquerque, New Mexico

  • Site US01015

    Garden City, New York

  • Site US01019

    Plainview, New York

  • Site US01069

    Cary, North Carolina

  • Site US01079

    Maiden, North Carolina

  • Site US01072

    Bristol, Tennessee

  • Site US01042

    Clarksville, Tennessee

  • Site US01056

    Knoxville, Tennessee

  • Site US01075

    Knoxville, Tennessee

  • Site US01078

    Knoxville, Tennessee

  • Site US01063

    Newport News, Virginia

  • Site CA15008

    Calgary, Alberta, Canada

  • Site CA15003

    Barrie, Ontario, Canada

  • Site CA15001

    Brampton, Ontario, Canada

  • Site CA15005

    Toronto, Ontario, Canada

  • Site CA15011

    Québec, Quebec, Canada

  • Site CA15002

    Sherbrooke, Quebec, Canada

  • Site CA15009

    Sherbrooke, Quebec, Canada

  • Site CA15014

    Victoriaville, Quebec, Canada

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.